Known severe valvular or structural heart disease (excluding left ventricular hypertrophy)
NYHA class III or IV heart failure or known reduced left ventricular function (ejection fraction (EF) \<30%)
EKG demonstrating significant pathology (e.g. myocardial infarction, atrial fibrillation, or any other cardial condition prohibiting start of study medication)
Life expancy \< 1 year
For women, current pregnancy or unprotected intercourse